Published in J Am Soc Nephrol on January 14, 2010
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84
Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis. J Am Soc Nephrol (2011) 1.75
Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med (2010) 1.62
Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med (2013) 1.62
Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol (2012) 1.61
Emerging role of autophagy in kidney function, diseases and aging. Autophagy (2012) 1.43
Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest (2014) 1.24
Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci U S A (2011) 1.15
Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One (2012) 1.14
Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics (2014) 1.14
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol (2010) 1.12
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A (2011) 1.05
PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol (2010) 1.05
Hypoxia-inducible factor-1α (HIF-1α) and autophagy in polycystic kidney disease (PKD). Am J Physiol Renal Physiol (2011) 1.03
Exposure to heavy ion radiation induces persistent oxidative stress in mouse intestine. PLoS One (2012) 1.03
Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta (2010) 1.02
The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci (2012) 0.99
Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol (2010) 0.99
Heparin-binding EGF-like growth factor induces heart interstitial fibrosis via an Akt/mTor/p70s6k pathway. PLoS One (2012) 0.99
Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. Pediatr Nephrol (2012) 0.97
Long-term differential changes in mouse intestinal metabolomics after γ and heavy ion radiation exposure. PLoS One (2014) 0.95
Molecular pathways and therapies in autosomal-dominant polycystic kidney disease. Physiology (Bethesda) (2015) 0.93
The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees. J Am Soc Nephrol (2015) 0.93
Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts. J Am Soc Nephrol (2013) 0.92
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle (2012) 0.91
Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol (2014) 0.90
Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease. Clin Transl Sci (2011) 0.89
Renal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice. Kidney Int (2014) 0.88
Calcium-mediated mechanisms of cystic expansion. Biochim Biophys Acta (2010) 0.88
Third-hit signaling in renal cyst formation. J Am Soc Nephrol (2011) 0.87
Clinical and molecular insights into tuberous sclerosis complex renal disease. Pediatr Nephrol (2010) 0.87
Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease. EBioMedicine (2016) 0.86
Mechanosensory Genes Pkd1 and Pkd2 Contribute to the Planar Polarization of Brain Ventricular Epithelium. J Neurosci (2015) 0.86
Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol (2012) 0.86
An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease. Nephrol Dial Transplant (2014) 0.85
Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat. PLoS One (2014) 0.85
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
Cilium, centrosome and cell cycle regulation in polycystic kidney disease. Biochim Biophys Acta (2011) 0.85
Therapeutic and space radiation exposure of mouse brain causes impaired DNA repair response and premature senescence by chronic oxidant production. Aging (Albany NY) (2013) 0.85
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2013) 0.84
Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells. Am J Physiol Renal Physiol (2013) 0.84
The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation. J Am Soc Nephrol (2014) 0.83
Radiation persistently promoted oxidative stress, activated mTOR via PI3K/Akt, and downregulated autophagy pathway in mouse intestine. Int J Biochem Cell Biol (2014) 0.82
An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr (2014) 0.81
Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation. J Biol Chem (2014) 0.81
Rapamycin delays salivary gland atrophy following ductal ligation. Cell Death Dis (2014) 0.80
2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. Am J Physiol Renal Physiol (2011) 0.80
Protracted upregulation of leptin and IGF1 is associated with activation of PI3K/Akt and JAK2 pathway in mouse intestine after ionizing radiation exposure. Int J Biol Sci (2015) 0.80
An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet (2014) 0.79
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol (2015) 0.79
Conditional mesenchymal disruption of pkd1 results in osteopenia and polycystic kidney disease. PLoS One (2012) 0.78
A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol (2016) 0.78
Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. PLoS One (2012) 0.78
Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Nephrology (Carlton) (2012) 0.77
MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease. J Am Soc Nephrol (2015) 0.77
Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease. J Am Soc Nephrol (2010) 0.76
Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev (2013) 0.76
Murine Models of Polycystic Kidney Disease. Drug Discov Today Dis Mech (2013) 0.76
Human Polycystin-2 Transgene Dose-Dependently Rescues ADPKD Phenotypes in Pkd2 Mutant Mice. Am J Pathol (2015) 0.76
Blocking rpS6 Phosphorylation Exacerbates Tsc1 Deletion-Induced Kidney Growth. J Am Soc Nephrol (2015) 0.75
Space radiation exposure persistently increased leptin and IGF1 in serum and activated leptin-IGF1 signaling axis in mouse intestine. Sci Rep (2016) 0.75
Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease. PLoS One (2016) 0.75
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch (2013) 0.75
Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling. J Am Heart Assoc (2016) 0.75
Bicaudal C mutation causes myc and TOR pathway up-regulation and polycystic kidney disease-like phenotypes in Drosophila. PLoS Genet (2017) 0.75
Slowing Polycystic Kidney Disease by Fasting. J Am Soc Nephrol (2015) 0.75
Emerging Therapies for Childhood Polycystic Kidney Disease. Front Pediatr (2017) 0.75
Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD. Physiol Rep (2016) 0.75
Cardiac dysfunction in Pkd1-deficient mice with phenotype rescue by galectin-3 knockout. Kidney Int (2016) 0.75
Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside. Kidney Res Clin Pract (2012) 0.75
RAPAMYCIN INCREASES LENGTH AND MECHANOSENSORY FUNCTION OF PRIMARY CILIA IN RENAL EPITHELIAL AND VASCULAR ENDOTHELIAL CELLS. Int Educ Res J (2016) 0.75
Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease. BMB Rep (2017) 0.75
Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis. J Cell Mol Med (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med (2008) 9.64
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A (2006) 4.56
A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med (2007) 4.40
Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int (2005) 2.13
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09
Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res (2004) 2.09
A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol (2004) 1.97
Bypass of lethality with mosaic mice generated by Cre-loxP-mediated recombination. Curr Biol (1996) 1.94
Pkd1 inactivation induced in adulthood produces focal cystic disease. J Am Soc Nephrol (2008) 1.65
Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One (2008) 1.64
Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int (2000) 1.58
Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J Lab Clin Med (2003) 1.56
Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol (2007) 1.50
Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol (2007) 1.42
Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res (2007) 1.35
Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol (2007) 1.35
Differential expression of the intermediate filament protein nestin during renal development and its localization in adult podocytes. J Am Soc Nephrol (2006) 1.34
Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant (2009) 1.16
Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol (2008) 1.11
Gene profiling of polycystic kidneys. Nephrol Dial Transplant (2006) 1.09
Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant (2009) 1.08
Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol Dial Transplant (2006) 0.96
Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int (2009) 0.96
SNAREs and epithelial cells. Methods (2003) 0.92
Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int (2005) 0.88
The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation (1992) 0.83
Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease. NDT Plus (2009) 0.79
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A (2006) 4.56
A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med (2007) 4.40
PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats. Am J Hum Genet (2002) 3.21
PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell (2002) 3.09
TRPP2 and TRPV4 form a polymodal sensory channel complex. J Cell Biol (2008) 2.88
Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell (2006) 2.64
Three-dimensional analysis of post-Golgi carrier exocytosis in epithelial cells. Nat Cell Biol (2003) 2.50
Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc Natl Acad Sci U S A (2002) 2.29
Polarity proteins control ciliogenesis via kinesin motor interactions. Curr Biol (2004) 2.28
Syntaxin 2 and endobrevin are required for the terminal step of cytokinesis in mammalian cells. Dev Cell (2003) 1.99
A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol (2004) 1.97
Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 1.77
Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J Am Soc Nephrol (2003) 1.70
T-cell factor/β-catenin activity is suppressed in two different models of autosomal dominant polycystic kidney disease. Kidney Int (2011) 1.69
Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling. J Biol Chem (2005) 1.64
Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol (2012) 1.61
Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol (2009) 1.58
Intragenic motifs regulate the transcriptional complexity of Pkhd1/PKHD1. J Mol Med (Berl) (2014) 1.56
Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J Lab Clin Med (2003) 1.56
Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure. Proc Natl Acad Sci U S A (2007) 1.52
A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2013) 1.49
Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell cell mechanical adhesion. Mol Biol Cell (2007) 1.47
Polyductin undergoes notch-like processing and regulated release from primary cilia. Hum Mol Genet (2007) 1.44
Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum Mol Genet (2007) 1.43
Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. Kidney Int (2004) 1.42
Identification and characterization of Pkhd1, the mouse orthologue of the human ARPKD gene. J Am Soc Nephrol (2002) 1.41
PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD). Hum Mutat (2004) 1.40
Linking cilia to Wnts. Nat Genet (2005) 1.40
Role of polycystins in renal tubulogenesis. Trends Cell Biol (2003) 1.35
Syntaxins 3 and 4 are concentrated in separate clusters on the plasma membrane before the establishment of cell polarity. Mol Biol Cell (2005) 1.32
Apical targeting of syntaxin 3 is essential for epithelial cell polarity. J Cell Biol (2006) 1.32
Loss of Bardet Biedl syndrome proteins causes defects in peripheral sensory innervation and function. Proc Natl Acad Sci U S A (2007) 1.32
Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease. Mol Genet Metab (2007) 1.31
Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference. J Pediatr (2006) 1.26
Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J Am Soc Nephrol (2006) 1.23
Direct interaction between Rab3b and the polymeric immunoglobulin receptor controls ligand-stimulated transcytosis in epithelial cells. Dev Cell (2002) 1.22
SNARE expression and localization in renal epithelial cells suggest mechanism for variability of trafficking phenotypes. Am J Physiol Renal Physiol (2002) 1.19
Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/reperfusion. J Am Soc Nephrol (2009) 1.19
Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci U S A (2011) 1.15
Milder presentation of recessive polycystic kidney disease requires presence of amino acid substitution mutations. J Am Soc Nephrol (2003) 1.13
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol (2010) 1.12
Image Segmentation, Registration and Visualization of Serial MR Images for Therapeutic Assessment of Polycystic Kidney Disease in Transgenic Mice. Conf Proc IEEE Eng Med Biol Soc (2005) 1.09
mTOR inhibitors in polycystic kidney disease. N Engl J Med (2010) 1.09
Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol (2002) 1.08
Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A (2011) 1.05
Polycystic kidney disease, cilia, and planar polarity. Methods Cell Biol (2009) 1.00
Bacteria-generated PtdIns(3)P recruits VAMP8 to facilitate phagocytosis. Traffic (2007) 0.97
Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells. Kidney Int (2009) 0.95
Pkd1 and Pkd2 are required for normal placental development. PLoS One (2010) 0.94
Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors. Hum Mol Genet (2005) 0.94
Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4α as a disease modifier. PLoS Genet (2012) 0.90
Syntaxin specificity of aquaporins in the inner medullary collecting duct. Am J Physiol Renal Physiol (2009) 0.89
Retinal pigment epithelial cells exhibit unique expression and localization of plasma membrane syntaxins which may contribute to their trafficking phenotype. J Cell Sci (2002) 0.89
The isolated polycystin-1 COOH-terminal can activate or block polycystin-1 signaling. Biochem Biophys Res Commun (2007) 0.88
A regulatory role of polycystin-1 on cystic fibrosis transmembrane conductance regulator plasma membrane expression. Cell Physiol Biochem (2006) 0.87
Third-hit signaling in renal cyst formation. J Am Soc Nephrol (2011) 0.87
Basolateral sorting of syntaxin 4 is dependent on its N-terminal domain and the AP1B clathrin adaptor, and required for the epithelial cell polarity. PLoS One (2011) 0.85
Refinement of the autosomal recessive polycystic kidney disease (PKHD1) interval and exclusion of an EF hand-containing gene as a PKHD1 candidate gene. Am J Med Genet (2002) 0.84
Heterologous expression of polycystin-1 inhibits endoplasmic reticulum calcium leak in stably transfected MDCK cells. Am J Physiol Renal Physiol (2008) 0.84
Macromolecular assembly of polycystin-2 intracytosolic C-terminal domain. Proc Natl Acad Sci U S A (2011) 0.81
Polycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1. Hum Mol Genet (2012) 0.81
ARPKD and ADPKD: first cousins or more distant relatives? J Am Soc Nephrol (2008) 0.81
Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol (2003) 0.80
A splice form of polycystin-2, lacking exon 7, does not interact with polycystin-1. Hum Mol Genet (2005) 0.80
Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen. Mol Cancer Ther (2006) 0.79
Ectopic expression of Cux1 is associated with reduced p27 expression and increased apoptosis during late stage cyst progression upon inactivation of Pkd1 in collecting ducts. Dev Dyn (2011) 0.78
Polycystic kidney disease: Polycystin-1 and polycystin-2--it's complicated. Nat Rev Nephrol (2013) 0.77
Progesterone induced mesenchymal differentiation and rescued cystic dilation of renal tubules of Pkd1(-/-) mice. Biochem Biophys Res Commun (2012) 0.77
Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Nephrology (Carlton) (2012) 0.77
Systems biology of polycystic kidney disease: a critical review. Wiley Interdiscip Rev Syst Biol Med (2015) 0.75
Regulation of nuclear functions--nucleocytoplasmic transport in context. Eur J Cell Biol (2004) 0.75
A dual tyrosine-leucine motif mediates myelin protein P0 targeting in MDCK cells. Glia (2006) 0.75